Clinical Research Directory
Browse clinical research sites, groups, and studies.
Nicotinamide Riboside in Ulcerative Colitis
Sponsor: University of Pittsburgh
Summary
This is a randomized, double-blind pilot study of Nicotinamide Riboside (NR) in Pediatric-onset Ulcerative Colitis (UC).
Key Details
Gender
All
Age Range
Any - 18 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-02-28
Completion Date
2026-06-30
Last Updated
2026-01-20
Healthy Volunteers
No
Conditions
Interventions
Nicotinamide Riboside Chloride
The intervention consists of 6 months to 1 year of daily oral therapy with Nicotinamide Riboside Chloride (Niagen) in addition to standard therapy.
Placebo
The intervention consists of 6 months to 1 year of daily oral therapy with placebo (Maltodextran capsules of similar size, shape and color as Niagen) in addition to standard therapy.
Standard of Care
Standard of Care
Locations (1)
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States